We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 417.6 -0.3674% AAPL 233.8413 1.0987% NVDA 131.796 -4.5441% GOOGL 165.105 0.0879% GOOG 166.53 0.1082% AMZN 186.945 -0.3173% META 585.25 -0.8756% AVGO 176.46 -3.2088% TSLA 220.1722 0.4619% TSM 187.28 -2.5649% LLY 912.1201 -1.8709% V 279.38 -0.4632% JPM 223.51 0.9166% UNH 558.27 -7.7849% NVO 117.56 -1.8534% WMT 81.405 1.3887% LVMUY 129.75 -6.7888% XOM 120.9 -2.5629% LVMHF 649.99 -6.7827% MA 507.335 0.1332%

Biomind Labs Inc.

Healthcare US BMNDF

0.2639USD
0.12(88.23%)

Last update at 2024-10-15T15:16:00Z

Day Range

0.260.26
LowHigh

52 Week Range

0.100.81
LowHigh

Fundamentals

  • Previous Close 0.14
  • Market Cap8.69M
  • Volume500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.62179M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.03

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -2.98550M -4.33236M -
Minority interest - - -
Net income -2.98550M -4.33236M -
Selling general administrative 2.32M 2.83M -
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.04M 0.03M -
Ebit - -3.42767M -36.68308M
Ebitda -2.93990M -4.30033M -
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -2.93483M -3.42767M -
Other operating expenses - - -
Interest expense 0.00136M 0.00371M 0.00000M
Tax provision - - -
Interest income - - -
Net interest income -0.00136M -0.00371M -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 0.00000M 0.00000M -
Total operating expenses 2.93M 3.43M -
Cost of revenue - - -
Total other income expense net -0.04931M -0.90098M -
Discontinued operations - - -
Net income from continuing ops -2.98550M -4.33236M -
Net income applicable to common shares - -4.33236M -36.68308M
Preferred stock and other adjustments - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Total assets 0.09M 2.53M -
Intangible assets - - -
Earning assets - - -
Other current assets - - -
Total liab 0.34M 0.33M -
Total stockholder equity -0.24766M 2.19M -
Deferred long term liab - - -
Other current liab - - -
Common stock - 11.10M 5.92M
Capital stock 11.10M 11.10M -
Retained earnings -13.43171M -10.44621M -6.11385M
Other liab - - -
Good will - - -
Other assets - - -
Cash 0.03M 2.27M -
Cash and equivalents - - -
Total current liabilities 0.34M 0.32M 0.22M
Current deferred revenue - - -
Net debt - - -
Short term debt - - -
Short long term debt - - -
Short long term debt total - - -
Other stockholder equity - 1.54M -
Property plant equipment - 0.09M -
Total current assets 0.04M 2.44M 0.03M
Long term investments - - -
Net tangible assets - 2.19M -0.18885M
Short term investments - - -
Net receivables - - -
Long term debt - - -
Inventory - - -
Accounts payable - 0.29M 0.03M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other - - -
Deferred long term asset charges - - -
Non current assets total 0.04M 0.09M -
Capital lease obligations 0.00816M 0.05M -
Long term debt total - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments 0.00000M -0.04434M -
Change to liabilities - 0.03M 1.31M
Total cashflows from investing activities - -0.04434M -0.04434M
Net borrowings - -0.03050M -0.03050M
Total cash from financing activities -0.03852M 4.47M 12.00M
Change to operating activities - -0.12998M -0.17790M
Net income -2.98550M -4.33236M -36.68308M
Change in cash -2.18941M 2.30M 2.30M
Begin period cash flow 2.27M 0.00000M -
End period cash flow 0.03M 2.27M -
Total cash from operating activities -2.15089M -2.12262M -12.00000M
Issuance of capital stock 0.00000M 4.50M -
Depreciation 0.04M 0.03M 0.03M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities - - -
Change to netincome - 2.29M 23.55M
Capital expenditures 0.00000M 0.04M 0.04M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 0.19M -0.10421M -
Stock based compensation 0.55M 1.38M -
Other non cash items 0.00136M 0.84M -
Free cash flow -2.15089M -2.16721M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BMNDF
Biomind Labs Inc.		 0.12 88.23% 0.26 - - - 183.79 -5.9923
NVO
Novo Nordisk A/S		 -2.22 1.85% 117.56 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.45 0.38% 119.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.745 0.36% 483.07 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.10 0.0099% 1014.35 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.

Biomind Labs Inc.

Building Ceibo Of. 002, Canelones, Uruguay

Key Executives

Name Title Year Born
Mr. Alejandro Antalich CEO & Director 1974
Mr. Oscar Alejandro Leon CFO & Director 1960
Ms. Paola Diaz Dellavalle Ph.D. Chief Scientific Officer NA
Mr. Juan Presa Chief Legal Officer NA
Ms. Magdalena Alvarez M.A. Head of Communication NA
Mr. Martin Daners Head of Quality Assurance & Regulatory Affairs NA
Dr. Marcelo Falchi Head of the Psychiatry Research Unit NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.